scholarly article | Q13442814 |
P356 | DOI | 10.1056/NEJMOA1801993 |
P698 | PubMed publication ID | 29552975 |
P50 | author | Phog Allen | Q2088566 |
Yemisi Takwoingi | Q30004015 | ||
Jonathan Deeks | Q47705879 | ||
Antti Rannikko | Q55079166 | ||
Samir S Taneja | Q56516562 | ||
Arnauld Villers | Q56531008 | ||
Boris Hadaschik | Q60647747 | ||
Caroline Moore | Q62606989 | ||
Mark Emberton | Q63968187 | ||
Alberto Briganti | Q67191563 | ||
Laurence Klotz | Q83824697 | ||
Veeru Kasivisvanathan | Q88094435 | ||
Peter A Pinto | Q90059716 | ||
Scott E Eggener | Q91336387 | ||
Inderbir S. Gill | Q95169970 | ||
P2093 | author name string | Lance A Mynderse | |
Stephen Morris | |||
Monique J Roobol | |||
Norman R Williams | |||
Alex Freeman | |||
Richard G Hindley | |||
Valeria Panebianco | |||
Lars Budäus | |||
Shonit Punwani | |||
Jim C Hu | |||
Giles Hellawell | |||
Franck Bladou | |||
Daniel Margolis | |||
Chris Brew-Graves | |||
Sébastien Crouzet | |||
Alain Ruffion | |||
Francesco Giganti | |||
Grégoire Robert | |||
Paras B Singh | |||
Silvan Boxler | |||
Jaspal Virdi | |||
Maneesh Ghei | |||
Markku H Vaarala | |||
Wulphert Venderink | |||
Geert M Villeirs | |||
Marcelo Borghi | |||
PRECISION Study Group Collaborators | |||
P407 | language of work or name | English | Q1860 |
P921 | main subject | magnetic resonance imaging | Q161238 |
prostate cancer | Q181257 | ||
P577 | publication date | 2018-03-18 | |
P1433 | published in | The New England Journal of Medicine | Q582728 |
P1476 | title | MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. |
Q58691149 | A Festschrift in Honor of Edward M. Messing, MD, FACS |
Q63965910 | A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy |
Q115033160 | A better way to biopsy in prostate cancer |
Q89701424 | A case report of multiple primary prostate tumors with differential drug sensitivity |
Q57824787 | A magnetic resonance imaging-based prediction model for prostate biopsy risk stratification |
Q92740583 | A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI-US fusion biopsy for prostate-cancer detection |
Q89639784 | A novel biparametric magnetic resonance imaging sequence provides a more efficient and similarly efficacious method of risk stratifying men clinically suspected of having prostate cancer |
Q93112102 | A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies |
Q90039554 | A propensity score matched analysis of the effects of African American race on the characteristics of regions of interests detected by magnetic resonance imaging of the prostate |
Q93134999 | A review of optimal prostate biopsy: indications and techniques |
Q91617685 | A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy |
Q101471273 | AUTHOR REPLY |
Q92258193 | Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer |
Q64262666 | Active surveillance for non-muscle invasive bladder cancer |
Q99403833 | Added Value of Biparametric MRI and TRUS-Guided Systematic Biopsies to Clinical Parameters in Predicting Adverse Pathology in Prostate Cancer |
Q99411604 | Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study |
Q52572975 | Adoption of Pre-Biopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. |
Q93360733 | Advances in prostate cancer imaging |
Q92863027 | Adverse pathology after radical prostatectomy: the prognostic role of cumulative cancer length >6-mm threshold in prostate cancer-positive biopsies |
Q59794433 | An annotated test-retest collection of prostate multiparametric MRI |
Q92449330 | Applying the PRECISION approach in biopsy naïve and previously negative prostate biopsy patients |
Q91787524 | Are we ready to adopt the European Association of Urology recommendations on multiparametric magnetic resonance imaging in the early detection of prostate cancer? |
Q64261177 | Artificial intelligence at the intersection of pathology and radiology in prostate cancer |
Q62490912 | Artificial intelligence in cancer imaging: Clinical challenges and applications |
Q92732671 | Assessment of the Minimal Targeted Biopsy Core Number per MRI Lesion for Improving Prostate Cancer Grading Prediction |
Q92662015 | Association Between Tumor Multifocality on Multi-parametric MRI and Detection of Clinically-Significant Prostate Cancer in Lesions with Prostate Imaging Reporting and Data System (PI-RADS) Score 4 |
Q90831294 | Author reply |
Q63884154 | BRCA2 and Other DDR Genes in Prostate Cancer |
Q101476441 | Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test |
Q92052777 | CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer |
Q58554027 | Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation |
Q97904987 | Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy? |
Q92065389 | Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI |
Q89555141 | Cancer Progress and Priorities: Prostate Cancer |
Q91640542 | Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer Screening |
Q92179430 | Characterizing the learning curve of MRI-US fusion prostate biopsies |
Q64097808 | Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies |
Q89235799 | Cognitive Versus Software Fusion for MRI-targeted Biopsy: Experience Before and After Implementation of Fusion |
Q90523248 | Combination of 68Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis |
Q97559360 | Combined MRI-targeted plus systematic confirmatory biopsy improves risk stratification for patients enrolling on active surveillance for prostate cancer |
Q91685412 | Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance |
Q92038496 | Commentary RE: The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer |
Q92473706 | Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis |
Q58570433 | Comparison of biparametric MRI to full multiparametric MRI for detection of clinically significant prostate cancer |
Q95261047 | Comparison of clinically significant prostate cancer detection by MRI cognitive biopsy and in-bore MRI-targeted biopsy for naïve biopsy patients |
Q90414258 | Complication Rates After TRUS Guided Transrectal Systematic and MRI-Targeted Prostate Biopsies in a High-Risk Region for Antibiotic Resistances |
Q91958397 | Concordance and Performance of 4Kscore® and SelectMDx® for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer |
Q63966136 | Constructing and Pilot Testing a Novel Prostate Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Phantom |
Q92213705 | Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings |
Q90048692 | Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study |
Q92861968 | Detection of individual prostate cancer via multiparametric magnetic resonance imaging in own material - initial experience |
Q92397846 | Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort |
Q89698266 | Diagnostic Accuracy and Value of Magnetic Resonance Imaging-Ultrasound Fusion Transperineal Targeted and Template Systematic Prostate Biopsy Based on Bi-parametric Magnetic Resonance Imaging |
Q92662009 | Diagnostic Performance of Prostate Multiparametric Magnetic Resonance Imaging in African-American Men |
Q64973435 | Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections. |
Q91855085 | Difference in MRI-guided biopsy cancer detection rates between individual clinicians |
Q92760179 | Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI |
Q92374355 | EDITORIAL COMMENT |
Q101471271 | EDITORIAL COMMENT |
Q64981272 | Early Second Round Targeted Biopsy of PI-RADS Score 3 or 4 in 256 Men With Persistent Suspicion of Prostate Cancer. |
Q92023285 | Effects of "real life" prostate MRI inter-observer variability on total needle samples and indication for biopsy |
Q59506757 | Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer |
Q94528362 | Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer |
Q95261507 | Establishing a novel prediction model for improving the positive rate of prostate biopsy |
Q93177852 | Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy |
Q95261579 | Evolution of prostate cancer diagnosis: retrospective analysis of magnetic resonance imaging/ultrasound fusion guided biopsies protocol in routine practice and patients management |
Q93334545 | Exclusive MRI-targeted biopsy: not so fast |
Q95933734 | External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study |
Q89843695 | External validation of the Martini nomogram for prediction of side-specific extraprostatic extension of prostate cancer in patients undergoing robot-assisted radical prostatectomy |
Q92003889 | Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer |
Q93025020 | Financial implications of biparametric prostate MRI |
Q91766786 | Focal Ablation of Prostate Cancer |
Q60920500 | Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives |
Q89686768 | Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI |
Q88766160 | Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer? |
Q93182653 | Free-hand transperineal prostate biopsy provides acceptable cancer detection and minimizes risk of infection: evolving experience with a 10-sector template |
Q93011457 | Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis |
Q64231463 | Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer |
Q92234351 | Genomics of lethal prostate cancer at diagnosis and castration resistance |
Q92596399 | Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer |
Q89955655 | Histomorphological analysis of false positive PI-RADS 4 and 5 lesions |
Q57457179 | Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate |
Q57725405 | How Would MRI-targeted Prostate Biopsy Alter Radiation Therapy Approaches in Treating Prostate Cancer? |
Q57171336 | Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications |
Q60923446 | Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification |
Q99569317 | Impact of Early Confirmatory Tests on Upgrading and Conversion to Treatment in Prostate Cancer Patients on Active Surveillance |
Q92397839 | Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies |
Q57111662 | Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy |
Q90257493 | Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns |
Q93147992 | Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance |
Q92710180 | Improvement of the intermediate risk prostate cancer sub-classification by integrating MRI and fusion biopsy features |
Q64910506 | In-bore biopsies of the prostate assisted by a remote-controlled manipulator at 1.5 T. |
Q93101418 | Increasing the use of active surveillance for prostate cancer in younger men |
Q93001050 | Independent Evaluation of the Respective Predictive Values for High-Grade Prostate Cancer of Clinical Information and RNA Biomarkers after Upfront MRI and Image-Guided Biopsies |
Q64105020 | Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model |
Q90005516 | Inflammation appears as high Prostate Imaging-Reporting and Data System scores on prostate magnetic resonance imaging (MRI) leading to false positive MRI fusion biopsy |
Q92090246 | Intercenter reproducibility of software-based fusion biopsies for grade group prediction when targeting suspicious MRI lesions |
Q90690736 | Intra- and interreader reproducibility of PI-RADSv2: A multireader study |
Q58551655 | Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy |
Q104073765 | Is a targeted biopsy-only approach for prostate cancer diagnosis ready for the prime time? |
Q92151543 | Is targeted biopsy really needed when performing systematic prostate biopsy to raise the detection rate for prostate cancer in patients with prostate-specific antigen ≤10 ng/mL? |
Q57105378 | Landmarks in prostate cancer |
Q64078907 | Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada |
Q88334686 | MRI improves diagnosis |
Q90989090 | MRI in active surveillance: a critical review |
Q57107955 | MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years |
Q90044063 | MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis |
Q57105670 | MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature |
Q92205706 | MRI-guided, transrectal, intraprostatic steam application as potential focal therapeutic modality for prostatic diseases in a large animal translational model: A feasibility follow-up study |
Q100316322 | MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort |
Q88579261 | Magnet Before the Needle Commentary on: MRI-targeted or Standard Biopsy for Prostate-cancer Diagnosis (PRECISION Trial) |
Q90058228 | Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer |
Q89639772 | Magnetic resonance imaging sequences for prostate cancer triage: two is a couple, three is a crowd? |
Q91815652 | Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations |
Q92955380 | Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management |
Q92962785 | Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review |
Q92051720 | Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions |
Q93086191 | Multimodality Imaging of Prostate Cancer |
Q91969165 | Multiparametric MRI for prostate cancer diagnosis: current status and future directions |
Q89543243 | Multiparametric MRI for prostate cancer: a national survey of patterns of practice among radiation oncologists in Spain |
Q92345413 | Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions |
Q89783216 | New Biopsy Techniques and Imaging Features of Transrectal Ultrasound for Targeting PI-RADS 4 and 5 Lesions |
Q94546975 | New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers |
Q64320006 | New oral anti-coagulation drugs and prostate biopsy: a call for guidelines |
Q100528986 | Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) |
Q96123493 | Oncological control following partial gland ablation for intermediate-risk prostate cancer |
Q93182732 | Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy |
Q91634714 | Optimization and repeatability of multipool chemical exchange saturation transfer MRI of the prostate at 3.0 T |
Q92830892 | PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design |
Q102319482 | PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer? |
Q89181551 | PRECISION delivers on the PROMIS of mpMRI in early detection |
Q92167793 | PROSTATEx Challenges for computerized classification of prostate lesions from multiparametric magnetic resonance images |
Q58107966 | PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics |
Q96813857 | Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling |
Q90199650 | Patient-Centered Outcomes From Multiparametric MRI and MRI-Guided Biopsy for Prostate Cancer: A Systematic Review |
Q92722967 | Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection |
Q59813234 | Performance of multiparametric MRI appears better when measured in patients who undergo radical prostatectomy |
Q90377740 | Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy |
Q92535853 | Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated? |
Q89396666 | Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies? |
Q99569316 | Post prostatectomy Pathologic Findings of Patients with Clinically Significant Prostate Cancer and no Significant PI-RADS Lesions on Preoperative Magnetic Resonance Imaging |
Q90464069 | Practice changing for prostate cancer: a vision of the future |
Q94475404 | Predicting clinically significant prostate cancer from quantitative image features including compressed sensing radial MRI of prostate perfusion using machine learning: comparison with PI-RADS v2 assessment scores |
Q64085522 | Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis |
Q94550790 | Prediction of prostate cancer Gleason score upgrading from biopsy to radical prostatectomy using pre-biopsy multiparametric MRI PIRADS scoring system |
Q96303424 | Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI |
Q92872291 | Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS |
Q92824548 | Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy |
Q90034400 | Preoperative staging using magnetic resonance imaging and risk of positive surgical margins after prostate-cancer surgery |
Q103798598 | Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer |
Q90466669 | Prognostic value of the SPOP mutant genomic subclass in prostate cancer |
Q89768162 | Prostate Cancer Academy 2019 Selected Summaries |
Q90609622 | Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy Naïve Men |
Q57106542 | Prostate Cancer in Primary Care |
Q89125002 | Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions |
Q90274615 | Prostate biopsy techniques and pre-biopsy prophylactic measures: variation in current practice patterns in the Netherlands |
Q58565438 | Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK |
Q91632680 | Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial |
Q94550311 | Prostate cancer screening research can benefit from network medicine: an emerging awareness |
Q57106301 | Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis |
Q64115030 | Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments |
Q92207247 | Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates |
Q90729984 | Quantifying the effect of biopsy lateral decubitus patient positioning compared to supine prostate MRI scanning on prostate translocation and distortion |
Q90660060 | Quantitative MRI or Machine Learning for Prostate MRI: Which Should You Use? |
Q92625861 | Re: Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer |
Q102219062 | Recent Advances and Current Role of Transperineal Prostate Biopsy |
Q91205471 | Rectal Swabs for Detecting Multidrug Resistant Bacteria Prior to Transrectal Prostate Fusion Biopsy: A Prospective Evaluation of Risk Factor Screening and Microbiologic Findings |
Q104610455 | Reply to The risk factors of upgrading in prostate cancer |
Q58562144 | Rethinking active surveillance for prostate cancer in African American men |
Q97643274 | Rethinking prostate cancer screening: could MRI be an alternative screening test? |
Q95261546 | Robotic-assisted magnetic resonance imaging ultrasound fusion results in higher significant cancer detection compared to cognitive prostate targeting in biopsy naive men |
Q90491182 | Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer |
Q91896696 | Role of novel imaging in the management of prostate cancer |
Q57107930 | Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance |
Q100395438 | Sectoral cancer detection and tolerability of freehand transperineal prostate biopsy under local anaesthesia |
Q90450297 | Spatial density and diversity of architectural histology in prostate cancer: influence on diffusion weighted magnetic resonance imaging |
Q100517496 | Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications |
Q98881626 | Sub-optimal Prediction of Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens by mpMRI-Targeted Biopsy |
Q92375021 | Systematic prostate biopsy still matters: A comprehensive analysis of MRI/TRUS-fusion targeted prostate biopsies across different indications |
Q103825407 | Target Biopsy and Core Number in Prostate Biopsy |
Q89925192 | Targeted Biopsy With Reduced Number of Cores: Optimal Sampling Scheme in Patients Undergoing Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Prostate Biopsy |
Q57109743 | Targets missed: predictors of MRI-targeted biopsy failing to accurately localize prostate cancer found on systematic biopsy |
Q92442572 | Teaching Urologists "How to Read Multi-Parametric Prostate MRIs Using PIRADSv2": Results of an iBook Pilot Study |
Q94521779 | Telomere-based risk models for the early diagnosis of clinically significant prostate cancer |
Q93385582 | Template for MR Visualization and Needle Targeting |
Q90439990 | Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial |
Q91935327 | The Accuracy of Prostate Magnetic Resonance Imaging Interpretation: Impact of the Individual Radiologist and Clinical Factors |
Q91564648 | The Association of Urologic Oncology Fellowship Training and Diagnostic Yield of Prostate Biopsy |
Q92029338 | The First In Vivo Needle-Based Optical Coherence Tomography in Human Prostate: A Safety and Feasibility Study |
Q57107304 | The Role of Imaging in Prostate Cancer Care Pathway: Novel Approaches to Urologic Management Challenges Along 10 Imaging Touch Points |
Q98224376 | The Role of Multiparametric MRI and MRI-targeted Biopsy in Detecting Clinically Significant Prostate Cancer in the Community Setting: A Retrospective Study |
Q64074113 | The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification |
Q92689529 | The Specific Choice of Transrectal Ultrasound-Guided Prostate Biopsy Scheme Based on Prostate Specific Antigen and Prostate Specific Antigen Density |
Q92454410 | The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations |
Q57107312 | The Use of Magnetic Resonance Imaging in the Prostate Cancer Primary Diagnostic Pathway: Is It Ready for Primetime? |
Q92705843 | The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods |
Q91123470 | The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy |
Q91808454 | The current role of prostate multiparametric magnetic resonance imaging |
Q91526392 | The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging |
Q98302233 | The effect of delaying transperineal fusion biopsy of the prostate for patients with suspicious MRI findings-Implications for the COVID-19 era |
Q102379251 | The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T1 relaxometry in patients with prostate cancer |
Q57105057 | The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging |
Q88770500 | The pendulum swings back: Screening for prostate cancer in 2018 |
Q92575413 | The primacy of multiparametric MRI in men with suspected prostate cancer |
Q90665408 | The pros and cons of screening |
Q96135129 | The role of MRI/TRUS fusion biopsy in the diagnosis of clinically significant prostate cancer |
Q93081310 | The role of Prostate Imaging Reporting and Data System score in Gleason 3 + 3 active surveillance candidates enrollment: a diagnostic meta-analysis |
Q102063210 | The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial |
Q92637533 | The role of multiparametric MRI in biopsy-naive prostate cancer |
Q104504831 | The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy |
Q92032404 | Three things about Gleason grading that just about everyone believes but that are almost certainly wrong |
Q64107477 | Three-dimensional greyscale transrectal ultrasound-guidance and biopsy core preembedding for detection of prostate cancer: Dutch clinical cohort study |
Q92341993 | To see or not to see - what renders prostate cancer visible? |
Q89728801 | Transperineal free-hand mpMRI fusion-targeted biopsies under local anesthesia: technique and feasibility from a single-centre prospective study |
Q64243026 | Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis |
Q91120894 | Use of MRI-Guided Biopsy for Selection and Follow-up of Men Undergoing Hemi-gland Cryoablation of Prostate Cancer |
Q93334539 | Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study |
Q90730005 | Utility of digital rectal examination in a population with prostate cancer treated with active surveillance |
Q92488218 | Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial |
Q90292338 | What are roles of multiparametric magnetic resonance imaging prior to transurethral resection of bladder tumor? |
Q104517654 | [French ccAFU guidelines - update 2020-2022: prostate cancer] |
Q90582185 | [Imaging in individualized uro-oncology] |
Search more.